Global Ceftriaxone Market Size, Share, Trends, Industry Growth by Route of Administration (Intravenous (IV), Intramuscular (IM)), by Application (Urinary Tract Infections, Intra-abdominal Infections, Endocarditis, Acute Bacterial Otitis Media, Meningitis, Pneumonia, Others), by End-User, by Region, and Forecast to 2030
Report ID: RCMA1223 | Report Format: PDF + Excel | Starting Price: 2680/- USD |The global ceftriaxone market size was valued at around USD 2 billion in 2022 and anticipated to register a significant CAGR of around 3% during the forecast period from 2023 to 2030. The market is influenced by several factors. Its wide spectrum of activity makes it a preferred choice for treating bacterial infections. The rise in antibiotic-resistant bacteria also drives its demand, as it remains effective against such strains. With a growing global population and increasing prevalence of bacterial infections, Ceftriaxone’s significance in healthcare is heightened. Moreover, investments in healthcare infrastructure, coupled with favorable regulations, further boost market growth. Continuous research and development may lead to the introduction of innovative formulations, sustaining their relevance in the pharmaceutical industry.
Market Snapshot:
| Benchmark Year | 2022 | ||
| Market Size | ~ USD 2 Billion in 2022 | ||
| Market Growth (CAGR) | ~ 3% (2023-2030) | ||
| Largest Market Share | North America | ||
| Analysis Period | 2020-2030 | ||
| Market Players | Roche Holding AG, Pfizer Inc., Hikma Pharmaceuticals plc, Novartis AG, Baxter International, Inc., and Fresenius Kabi AG |
Market Drivers:
- Increasing Prevalence of Bacterial Infections: The growing incidence of bacterial infections, including complicated respiratory tract infections, urinary tract infections, and meningitis, among others, drives the demand for Ceftriaxone.
- Rise in Antibiotic-Resistant Bacteria: Antibiotic resistance remains a significant global health concern. Ceftriaxone’s effectiveness against certain antibiotic-resistant bacteria makes it an essential treatment option, increasing its demand.
- Wide Spectrum of Activity: Ceftriaxone’s ability to treat a broad range of bacterial infections makes it a versatile and preferred choice for healthcare providers, leading to a higher market demand.
- Hospital-Acquired Infections: Hospital-acquired infections (nosocomial infections) continue to be a major challenge for healthcare facilities. Ceftriaxone is often used to treat these infections, contributing to its market growth.
- Global Population Growth: As the global population continues to increase, the number of individuals susceptible to bacterial infections also rises, which, in turn, fuels the demand for antibiotics like Ceftriaxone.
- Investments in Healthcare Infrastructure: Improving healthcare infrastructure in developing countries allows for better access to antibiotics, including Ceftriaxone, leading to increased sales.
- Innovation and Research: Ongoing research and development in the field of antibiotics, including Ceftriaxone, may lead to the introduction of new formulations or combination therapies, further driving market growth.
- Regulatory Support: Favorable regulations and policies related to antibiotic use and access can positively impact the market for Ceftriaxone.
To know more about the research study, request sample papers
Market Insights:
The global ceftriaxone market is bifurcated into the route of administration, application, end-user, and geography. On the basis of end-user, The Hospitals and Clinics segment has been a dominant and growing market for ceftriaxone, driven by various factors. The increasing demand for healthcare services due to population growth and aging has led to a higher number of hospitalizations and clinic visits. As patients seek treatment for bacterial infections in these healthcare settings, the demand for antibiotics like ceftriaxone rises. Furthermore, the prevalence of bacterial infections remains a significant global health concern. Hospitals and clinics are at the forefront of treating such infections, making them key consumers of Ceftriaxone. The antibiotic’s broad spectrum of activity and efficacy against susceptible bacteria make it a versatile choice in managing various infections encountered in these healthcare settings.
Hospitals and Clinics: Hospitals, both large medical centers, and smaller community hospitals, are significant end-users of Ceftriaxone. This is due to their high patient volume and the ability to manage severe and complicated infections that may require intravenous administration. Clinics, including outpatient facilities, also contribute to the market as they treat a wide range of infections where Ceftriaxone is effective.
Ambulatory Surgical Centers (ASCs): Ambulatory surgical centers are specialized facilities that provide outpatient surgical procedures. These centers may use Ceftriaxone for prophylactic purposes before surgery to prevent infection or post-surgery if an infection occurs.
Others: The “Others” category may include various healthcare settings where Ceftriaxone is utilized. This could include long-term care facilities, nursing homes, home healthcare, and other specialty healthcare providers.
The ceftriaxone market research report presents the analysis of each segment from 2020 to 2030 considering 2022 as the base year for the research. The compounded annual growth rate (CAGR) for each respective segment is calculated for the forecast period from 2023 to 2030.
Historical & Forecast Period
- 2020-21 – Historical Year
- 2022 – Base Year
- 2023-2030 – Forecast Period
Market Segmentation:
By Route of Administration:
- Including Intravenous (IV)
- Intramuscular (IM)
By Application:
- Urinary Tract Infections
- Intra-abdominal Infections
- Endocarditis
- Acute Bacterial Otitis Media
- Meningitis
- Pneumonia
- Others
By End-User:
- Hospitals and Clinics
- Ambulatory Surgical Centers
- Others
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Regional Analysis:
In 2022, North America held the largest revenue share of the global ceftriaxone market and expected to grow at the same trend over the forecast period. The region is expected to remain a highly lucrative market throughout the forecast period. Its dominant position can be attributed to a rising incidence of bacterial infections, coupled with the widespread adoption of technologically advanced products, substantial healthcare spending, early access to cutting-edge technologies, and favorable funding from governments and charitable trusts for healthcare research. These factors are projected to drive significant growth in the ceftriaxone market in the coming years. Within North America, the United States emerged as the dominant player, benefiting from the presence of key industry players.
On the other hand, Asia Pacific is poised to witness the fastest market development during the forecast period. This region is projected to experience a high compound annual growth rate (CAGR) during the forecast period from 2023 to 2030, mainly due to its substantial patient base, particularly in countries like India and China. The increasing prevalence of bacterial infections and the growing healthcare infrastructure in the region are anticipated to contribute to the significant expansion of the Ceftriaxone market in Asia Pacific.
Competitive Assessment:
Some of the major market players operating in the global ceftriaxone market are Roche Holding AG, Pfizer Inc., Hikma Pharmaceuticals plc, Novartis AG, Baxter International, Inc., and Fresenius Kabi AG. Companies are exploring markets through expansion, new investment, the introduction of new services, and collaboration as their preferred strategies. Players are exploring new geography through expansion and acquisition to gain a competitive advantage through joint synergy.
Key Companies:
- Roche Holding AG
- Pfizer Inc.
- Hikma Pharmaceuticals plc
- Novartis AG
- Baxter International, Inc.
- Fresenius Kabi AG
- Sanofi S.A.
- Aurobindo Pharma
- ACS DOBFAR S.P.A.
- Lupin Pharmaceuticals, Inc.
- Orchid Pharma
- Nectar Lifesciences Ltd.
Key Questions Answered by Ceftriaxone Market Report
- Global ceftriaxone market forecasts from 2023-2030
- Regional market forecasts from 2023-2030 covering Asia-Pacific, North America, Europe, Middle East & Africa, and Latin America
- Country-level forecasts from 2023-2030 covering 15 major countries from the regions as mentioned above
- Ceftriaxone submarket forecasts from 2023-2030 covering the market by route of administration, application, end-user, and geography
- Various industry models such as SWOT analysis, Value Chain Analysis about the market
- Analysis of the key factors driving and restraining the growth of the global, regional, and country-level ceftriaxone markets from 2023-2030
- Competitive Landscape and market positioning of top 10 players operating in the market
1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.4. Assumptions
2. Executive Summary
2.1. Global Ceftriaxone Market Portraiture
2.2. Global Ceftriaxone Market, by Route of Administration, 2022 (USD Mn)
2.3. Global Ceftriaxone Market, by Application, 2022 (USD Mn)
2.4. Global Ceftriaxone Market, by End-User, 2022 (USD Mn)
2.5. Global Ceftriaxone Market, by Geography, 2022 (USD Mn)
3. Global Ceftriaxone Market Analysis
3.1. Ceftriaxone Market Overview
3.2. Market Inclination Insights
3.3. Market Dynamics
3.3.1. Drivers
3.3.2. Challenges
3.3.3. Opportunities
3.4. Attractive Investment Proposition
3.5. Competitive Analysis
3.6. Porter’s Five Force Analysis
3.6.1. Bargaining Power of Suppliers
3.6.2. Bargaining Power of Buyers
3.6.3. Threat of New Entrants
3.6.4. Threat of Substitutes
3.6.5. Degree of Competition
3.7. PESTLE Analysis
4. Global Ceftriaxone Market By Route of Administration, 2020 – 2030 (USD Mn)
4.1. Overview
4.2. Intravenous (IV)
4.3. Intramuscular (IM)
5. Global Ceftriaxone Market By Application, 2020 – 2030 (USD Mn)
5.1. Overview
5.2. Urinary Tract Infections
5.3. Intra-abdominal Infections
5.4. Endocarditis
5.5. Acute Bacterial Otitis Media
5.6. Meningitis
5.7. Pneumonia
5.8. Others
6. Global Ceftriaxone Market By End-User, 2020 – 2030 (USD Mn)
6.1. Overview
6.2. Hospitals and Clinics
6.3. Ambulatory Surgical Centers
6.4. Others
7. North America Ceftriaxone Market Analysis and Forecast, 2020 – 2030 (USD Mn)
7.1. Overview
7.2. North America Ceftriaxone Market by Route of Administration, (2020-2030 USD Mn)
7.3. North America Ceftriaxone Market by Application, (2020-2030 USD Mn)
7.4. North America Ceftriaxone Market by End-User, (2020-2030 USD Mn)
7.5. North America Ceftriaxone Market by Country, (2020-2030 USD Mn)
7.5.1. U.S.
7.5.1.1. U.S. Ceftriaxone Market by Route of Administration, (2020-2030 USD Mn)
7.5.1.2. U.S. Ceftriaxone Market by Application, (2020-2030 USD Mn)
7.5.1.3. U.S. Ceftriaxone Market by End-User, (2020-2030 USD Mn)
7.5.2. Canada
7.5.2.1. Canada Ceftriaxone Market by Route of Administration, (2020-2030 USD Mn)
7.5.2.2. Canada Ceftriaxone Market by Application, (2020-2030 USD Mn)
7.5.2.3. Canada Ceftriaxone Market by End-User, (2020-2030 USD Mn)
8. Europe Ceftriaxone Market Analysis and Forecast, 2020 - 2030 (USD Mn)
8.1. Overview
8.2. Europe Ceftriaxone Market by Route of Administration, (2020-2030 USD Mn)
8.3. Europe Ceftriaxone Market by Application, (2020-2030 USD Mn)
8.4. Europe Ceftriaxone Market by End-User, (2020-2030 USD Mn)
8.5. Europe Ceftriaxone Market by Country, (2020-2030 USD Mn)
8.5.1. Germany
8.5.1.1. Germany Ceftriaxone Market by Route of Administration, (2020-2030 USD Mn)
8.5.1.2. Germany Ceftriaxone Market by Application, (2020-2030 USD Mn)
8.5.1.3. Germany Ceftriaxone Market by End-User, (2020-2030 USD Mn)
8.5.2. U.K.
8.5.2.1. U.K. Ceftriaxone Market by Route of Administration, (2020-2030 USD Mn)
8.5.2.2. U.K. Ceftriaxone Market by Application, (2020-2030 USD Mn)
8.5.2.3. U.K. Ceftriaxone Market by End-User, (2020-2030 USD Mn)
8.5.3. France
8.5.3.1. France Ceftriaxone Market by Route of Administration, (2020-2030 USD Mn)
8.5.3.2. France Ceftriaxone Market by Application, (2020-2030 USD Mn)
8.5.3.3. France Ceftriaxone Market by End-User, (2020-2030 USD Mn)
8.5.4. Spain
8.5.4.1. Spain Ceftriaxone Market by Route of Administration, (2020-2030 USD Mn)
8.5.4.2. Spain Ceftriaxone Market by Application, (2020-2030 USD Mn)
8.5.4.3. Spain Ceftriaxone Market by End-User, (2020-2030 USD Mn)
8.5.5. Italy
8.5.5.1. Italy Ceftriaxone Market by Route of Administration, (2020-2030 USD Mn)
8.5.5.2. Italy Ceftriaxone Market by Application, (2020-2030 USD Mn)
8.5.5.3. Italy Ceftriaxone Market by End-User, (2020-2030 USD Mn)
8.5.6. Rest of Europe
8.5.6.1. Rest of Europe Ceftriaxone Market by Route of Administration, (2020-2030 USD Mn)
8.5.6.2. Rest of Europe Ceftriaxone Market by Application, (2020-2030 USD Mn)
8.5.6.3. Rest of Europe Ceftriaxone Market by End-User, (2020-2030 USD Mn)
9. Asia Pacific Ceftriaxone Market Analysis and Forecast, 2020 - 2030 (USD Mn)
9.1. Overview
9.2. Asia Pacific Ceftriaxone Market by Route of Administration, (2020-2030 USD Mn)
9.3. Asia Pacific Ceftriaxone Market by Application, (2020-2030 USD Mn)
9.4. Asia Pacific Ceftriaxone Market by End-User, (2020-2030 USD Mn)
9.5. Asia Pacific Ceftriaxone Market by Country, (2020-2030 USD Mn)
9.5.1. China
9.5.1.1. China Ceftriaxone Market by Route of Administration, (2020-2030 USD Mn)
9.5.1.2. China Ceftriaxone Market by Application, (2020-2030 USD Mn)
9.5.1.3. China Ceftriaxone Market by End-User, (2020-2030 USD Mn)
9.5.2. Japan
9.5.2.1. Japan Ceftriaxone Market by Route of Administration, (2020-2030 USD Mn)
9.5.2.2. Japan Ceftriaxone Market by Application, (2020-2030 USD Mn)
9.5.2.3. Japan Ceftriaxone Market by End-User, (2020-2030 USD Mn)
9.5.3. India
9.5.3.1. India Ceftriaxone Market by Route of Administration, (2020-2030 USD Mn)
9.5.3.2. India Ceftriaxone Market by Application, (2020-2030 USD Mn)
9.5.3.3. India Ceftriaxone Market by End-User, (2020-2030 USD Mn)
9.5.4. South Korea
9.5.4.1. South Korea Ceftriaxone Market by Route of Administration, (2020-2030 USD Mn)
9.5.4.2. South Korea Ceftriaxone Market by Application, (2020-2030 USD Mn)
9.5.4.3. South Korea Ceftriaxone Market by End-User, (2020-2030 USD Mn)
9.5.5. Rest of Asia Pacific
9.5.5.1. Rest of Asia Pacific Ceftriaxone Market by Route of Administration, (2020-2030 USD Mn)
9.5.5.2. Rest of Asia Pacific Ceftriaxone Market by Application, (2020-2030 USD Mn)
9.5.5.3. Rest of Asia Pacific Ceftriaxone Market by End-User, (2020-2030 USD Mn)
10. Latin America (LATAM) Ceftriaxone Market Analysis and Forecast, 2020 - 2030 (USD Mn)
10.1. Overview
10.2. Latin America Ceftriaxone Market by Route of Administration, (2020-2030 USD Mn)
10.3. Latin America Ceftriaxone Market by Application, (2020-2030 USD Mn)
10.4. Latin America Ceftriaxone Market by End-User, (2020-2030 USD Mn)
10.5. Latin America Ceftriaxone Market by Country, (2020-2030 USD Mn)
10.5.1. Brazil
10.5.1.1. Brazil Ceftriaxone Market by Route of Administration, (2020-2030 USD Mn)
10.5.1.2. Brazil Ceftriaxone Market by Application, (2020-2030 USD Mn)
10.5.1.3. Brazil Ceftriaxone Market by End-User, (2020-2030 USD Mn)
10.5.2. Mexico
10.5.2.1. Mexico Ceftriaxone Market by Route of Administration, (2020-2030 USD Mn)
10.5.2.2. Mexico Ceftriaxone Market by Application, (2020-2030 USD Mn)
10.5.2.3. Mexico Ceftriaxone Market by End-User, (2020-2030 USD Mn)
10.5.3. Rest of Latin America
10.5.3.1. Rest of Latin America Ceftriaxone Market by Route of Administration, (2020-2030 USD Mn)
10.5.3.2. Rest of Latin America Ceftriaxone Market by Application, (2020-2030 USD Mn)
10.5.3.3. Rest of Latin America Ceftriaxone Market by End-User, (2020-2030 USD Mn)
11. Middle East and Africa Ceftriaxone Market Analysis and Forecast, 2020 - 2030 (USD Mn)
11.1. Overview
11.2. MEA Ceftriaxone Market by Route of Administration, (2020-2030 USD Mn)
11.3. MEA Ceftriaxone Market by Application, (2020-2030 USD Mn)
11.4. MEA Ceftriaxone Market by End-User, (2020-2030 USD Mn)
11.5. Middle East and Africa Ceftriaxone Market, by Country, (2020-2030 USD Mn)
11.5.1. GCC
11.5.1.1. GCC Ceftriaxone Market by Route of Administration, (2020-2030 USD Mn)
11.5.1.2. GCC Ceftriaxone Market by Application, (2020-2030 USD Mn)
11.5.1.3. GCC Ceftriaxone Market by End-User, (2020-2030 USD Mn)
11.5.2. South Africa
11.5.2.1. South Africa Ceftriaxone Market by Route of Administration, (2020-2030 USD Mn)
11.5.2.2. South Africa Ceftriaxone Market by Application, (2020-2030 USD Mn)
11.5.2.3. South Africa Ceftriaxone Market by End-User, (2020-2030 USD Mn)
11.5.3. Rest of MEA
11.5.3.1. Rest of MEA Ceftriaxone Market by Route of Administration, (2020-2030 USD Mn)
11.5.3.2. Rest of MEA Ceftriaxone Market by Application, (2020-2030 USD Mn)
11.5.3.3. Rest of MEA Ceftriaxone Market by End-User, (2020-2030 USD Mn)
12. Company Profiles
12.1. Roche Holding AG
12.1.1. Business Description
12.1.2. Financial Health and Budget Allocation
12.1.3. Product Positions/Portfolio
12.1.4. Recent Development
12.1.5. SWOT Analysis
12.2. Pfizer Inc.
12.2.1. Business Description
12.2.2. Financial Health and Budget Allocation
12.2.3. Product Positions/Portfolio
12.2.4. Recent Development
12.2.5. SWOT Analysis
12.3. Hikma Pharmaceuticals plc
12.3.1. Business Description
12.3.2. Financial Health and Budget Allocation
12.3.3. Product Positions/Portfolio
12.3.4. Recent Development
12.3.5. SWOT Analysis
12.4. Novartis AG
12.4.1. Business Description
12.4.2. Financial Health and Budget Allocation
12.4.3. Product Positions/Portfolio
12.4.4. Recent Development
12.4.5. SWOT Analysis
12.5. Baxter International, Inc.
12.5.1. Business Description
12.5.2. Financial Health and Budget Allocation
12.5.3. Product Positions/Portfolio
12.5.4. Recent Development
12.5.5. SWOT Analysis
12.6. Fresenius Kabi AG
12.6.1. Business Description
12.6.2. Financial Health and Budget Allocation
12.6.3. Product Positions/Portfolio
12.6.4. Recent Development
12.6.5. SWOT Analysis
12.7. Sanofi S.A.
12.7.1. Business Description
12.7.2. Financial Health and Budget Allocation
12.7.3. Product Positions/Portfolio
12.7.4. Recent Development
12.7.5. SWOT Analysis
12.8. Aurobindo Pharma
12.8.1. Business Description
12.8.2. Financial Health and Budget Allocation
12.8.3. Product Positions/Portfolio
12.8.4. Recent Development
12.8.5. SWOT Analysis
12.9. ACS DOBFAR S.P.A.
12.9.1. Business Description
12.9.2. Financial Health and Budget Allocation
12.9.3. Product Positions/Portfolio
12.9.4. Recent Development
12.9.5. SWOT Analysis
12.10. Lupin Pharmaceuticals, Inc.
12.10.1. Business Description
12.10.2. Financial Health and Budget Allocation
12.10.3. Product Positions/Portfolio
12.10.4. Recent Development
12.10.5. SWOT Analysis
12.11. Orchid Pharma
12.11.1. Business Description
12.11.2. Financial Health and Budget Allocation
12.11.3. Product Positions/Portfolio
12.11.4. Recent Development
12.11.5. SWOT Analysis
12.12. Nectar Lifesciences Ltd.
12.12.1. Business Description
12.12.2. Financial Health and Budget Allocation
12.12.3. Product Positions/Portfolio
12.12.4. Recent Development
12.12.5. SWOT Analysis
$ 4800/- Multi User License $ 6800/- Corporate License
- Markets in over 100+ countries analyzed granularly
- 35% of our total client are returning clients
- 1000+ customers globally
- 100+ paid data sources mined to bring cutting-edge insights
- 24x5 availability - we are always there when you need us
- "Free of Cost Report Customization" is available
- Request a regional report at Best Price
- Our expert team will assist you with all research need and customization
- Our expert research analysts will resolve your every query before and after purchasing the report
Our Clients
